-
Autor
Advani, Ranjana H 1 Ansell, Stephen M 1 Arai, Sally 1 Azzi, Jacues 1 Bachanova, Veronika 1 Baidoun, Firas 1 Blum, Kristie A 1 Chang, Cheryl 1 Choi, Yun 1 Desai, Sanjal H 1 Diefenbach, Catherine 1 Dorritie, Kathleen 1 Evens, Andrew M 1 Fusco, Brendon 1 Goyal, Gaurav 1 Harris, Elyse I 1 Hatic, Haris 1 Ibrahim, Uroosa 1 Iyengar, Siddharth 1 Jagadeesh, Deepa 1
-
Pracoviště
Cleveland Clinic Foundation Cleveland OH 1 Department of Clinical Hematology Cha... 1 Department of Hemato Oncology Faculty... 1 Department of Hematology and Medical ... 1 Department of Internal Medicine Hemat... 1 Department of Medicine Rutgers Cancer... 1 Division of Hematology Department of ... 1 Division of Hematology Mayo Clinic Ro... 1 Division of Hematology Medical Oncolo... 1 Division of Hematology Oncology and T... 1 Division of Hematology and Oncology D... 1 Division of Hematology and Oncology D... 1 Division of Hematology and Oncology D... 1 Division of Oncology Department of Me... 1 Division of Oncology Department of Me... 1 Icahn School of Medicine Mount Sinai ... 1 Perlmutter Cancer Center NYU Grossman... 1 The Sidney Kimmel Comprehensive Cance... 1 University Hospital and Faculty of Me... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
Autor
Advani, Ranjana H 1 Ansell, Stephen M 1 Arai, Sally 1 Azzi, Jacues 1 Bachanova, Veronika 1 Baidoun, Firas 1 Blum, Kristie A 1 Chang, Cheryl 1 Choi, Yun 1 Desai, Sanjal H 1 Diefenbach, Catherine 1 Dorritie, Kathleen 1 Evens, Andrew M 1 Fusco, Brendon 1 Goyal, Gaurav 1 Harris, Elyse I 1 Hatic, Haris 1 Ibrahim, Uroosa 1 Iyengar, Siddharth 1 Jagadeesh, Deepa 1
-
Pracoviště
Cleveland Clinic Foundation Cleveland OH 1 Department of Clinical Hematology Cha... 1 Department of Hemato Oncology Faculty... 1 Department of Hematology and Medical ... 1 Department of Internal Medicine Hemat... 1 Department of Medicine Rutgers Cancer... 1 Division of Hematology Department of ... 1 Division of Hematology Mayo Clinic Ro... 1 Division of Hematology Medical Oncolo... 1 Division of Hematology Oncology and T... 1 Division of Hematology and Oncology D... 1 Division of Hematology and Oncology D... 1 Division of Hematology and Oncology D... 1 Division of Oncology Department of Me... 1 Division of Oncology Department of Me... 1 Icahn School of Medicine Mount Sinai ... 1 Perlmutter Cancer Center NYU Grossman... 1 The Sidney Kimmel Comprehensive Cance... 1 University Hospital and Faculty of Me... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
Europe PubMed Central od 2016
ROAD: Directory of Open Access Scholarly Resources od 2016
PubMed
37729621
DOI
10.1182/bloodadvances.2023011205
Knihovny.cz E-zdroje
In the pre-novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3 years. Recently, checkpoint inhibitors (CPI) and brentuximab vedotin (BV) have improved the depth and durability of response in this population. Here, we report the estimate of PPS in patients with relapsed cHL after ASCT in the era of CPI and BV. In this multicenter retrospective study of 15 participating institutions, adult patients with relapsed cHL after ASCT were included. Study objective was postprogression overall survival (PPS), defined as the time from posttransplant progression to death or last follow-up. Of 1158 patients who underwent ASCT, 367 had progressive disease. Median age was 34 years (range, 27-46) and 192 were male. Median PPS was 114.57 months (95% confidence interval [CI], 91-not achieved) or 9.5 years. In multivariate analysis, increasing age, progression within 6 months, and pre-ASCT positive positron emission tomography scan were associated with inferior PPS. When adjusted for these features, patients who received CPI, but not BV, as first treatment for post-ASCT progression had significantly higher PPS than the no CPI/no BV group (hazard ratio, 3.5; 95% CI, 1.6-7.8; P = .001). Receipt of allogeneic SCT (Allo-SCT) did not improve PPS. In the era of novel agents, progressive cHL after ASCT had long survival that compares favorably with previous reports. Patients who receive CPI as first treatment for progression had higher PPS. Receipt to Allo-SCT was not associated with PPS in this population.
- MeSH
- brentuximab vedotin MeSH
- dospělí MeSH
- Hodgkinova nemoc * terapie MeSH
- imunokonjugáty * MeSH
- kojenec MeSH
- lidé MeSH
- retrospektivní studie MeSH
- transplantace kmenových buněk MeSH
- Check Tag
- dospělí MeSH
- kojenec MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.